FTC, Illumina Clash On Merger's Potential To Win Cancer War

By Bryan Koenig (August 24, 2021, 9:40 PM EDT) -- Federal Trade Commission staffers opened their in-house challenge to Illumina's $8 billion reacquisition of Grail with a warning Tuesday that the merger will inhibit competition necessary to win "the war on cancer," painting a picture that served as a mirror image of the companies' arguments.

The FTC lawyers not only rejected claims by Illumina Inc. and Grail Inc. that their merger is the best way to accelerate the development, regulatory approval, insurance reimbursement and marketing of Grail's "life-saving" multi-cancer early detection, or MCED, tests, they also asserted that the "vertical" tie-up would harm competition where the supply chain already is most...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!